Foa2022 - Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure Response Prevention Augmentation, A Randomized Clinical Trial
- Year read:#read2022
- Subject: OCD
- Bibtex: @foa2022
- Bibliography: Foa, E. B., Simpson, H. B., Gallagher, T., Wheaton, M. G., Gershkovich, M., Schmidt, A. B., Huppert, J. D., Imms, P., Campeas, R. B., Cahill, S., DiChiara, C., Tsao, S. D., Puliafico, A., Chazin, D., Asnaani, A., Moore, K., Tyler, J., Steinman, S. A., Sanches-LaCay, A., … Rosenfield, D. (2022). Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. JAMA Psychiatry, 79(3), 193. https://doi.org/10.1001/jamapsychiatry.2021.3997
Patients who benefit from EX/RP can safely discontinue SSRI with non-inferior outcomes compared to patients who continue their SSRI [@foa2022].
- n = 137 OCD patients. Everyone got EX/RP and those who scored Y-BOCS ≤14 (n = 103) were randomized to either continue SRI or taper to placebo.
- Taper group had noninferior results compared with patients in continuation group (Y-BOCS diff = -0.04 [95% CI inf to 2.28])